Valganciclovir
Valganciclovir has been studied in 2 papers since 2025: 1 observational study in people, 1 review; 2 in the past year. The newest paper, Mar 1, 2026: “Antiviral Treatment of Herpes Simplex Virus Decreases the Risk of Alzheimer's Disease and Dementia”.
See all 3 papers on valganciclovir
At a glance
16 trials, none about aging, 5 with no results posted.
Cells, worms or flies, mice and humans: nothing yet.
- 16 trials, none about aging, 5 with no results posted
- Humans1
Who is developing valganciclovir?
1 company: Viracta Therapeutics.
- Companies
- Viracta TherapeuticsPhase 1/2Epstein-Barr virus-associated lymphoma, lymphoproliferative disorders
Trial sponsors
Company3 trialsPhase 4624 people
Company2 trialsPhase 311 people
Company1 trialPhase 3601 people
Company1 trialPhase 3352 people
Company1 trialPhase 3212 people
Company2 trialsPhase 22 people
Company1 trialPhase 1/264 people
University of California, San Francisco
1 trialPhase 3360 people
Latest
2 papers in 12 monthsJournal of Drugs in Dermatology
Antiviral Treatment of Herpes Simplex Virus Decreases the Risk of Alzheimer's Disease and Dementia
Cohort study of 615,324 peopleDementia
Journal of Alzheimer's Disease
Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis
Meta-analysis of observational studiesDementia